Previous 10 | Next 10 |
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Melanoma Test (DMT) has tested more than 200,000 suspicious pigmented lesions. The DMT use...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced agreements with a Blues plan in South Carolina and the United Mine Workers of America Health and Retirement ...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that its board of directors (“the board”) has granted an equity award to its new chief executi...
2023-05-09 10:49:56 ET DermTech ( NASDAQ: DMTK ) has announced the appointment of Bret Christensen, previously chief commercial officer of Insulet, as president, chief executive officer. Mr. Christensen succeeds Dr. John Dobak, who stepped down as president, chief executive of...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Bret Christensen, previously chief commercial officer of Insulet, as president, chief exe...
2023-05-04 21:59:03 ET DermTech, Inc. (DMTK) Q1 2023 Results Conference Call May 04, 2023 05:00 PM ET Company Participants Steve Kunszabo - Head, IR Dr. John Dobak - President and CEO Kevin Sun - CFO Conference Call Participants Mark Massaro - BTIG ...
2023-05-04 16:51:25 ET DermTech press release ( NASDAQ: DMTK ): Q1 GAAP EPS of -$1.02 misses by $0.11 . Revenue of $3.48M (-5.9% Y/Y) beats by $0.01M . For further details see: DermTech GAAP EPS of -$1.02 misses by $0.11, revenue of $3.48M beats by $0.01M
- Covered lives increased to 126 million - Cash runway through the third quarter of 2024 DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported it...
To elevate the importance of regular skin checks, DermTech announces its third annual #Stickit2Melanoma campaign for Melanoma Awareness Month DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a physician-founded, member-focused and community-based not-for-profit health plan in New ...